Duality Biotherapeutics Clears HKEX Hearing, Set for IPO with $2.7B Valuation
Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully...
Duality Biotherapeutics
Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules
China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...
3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303
China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...
Duality Biologics and Avenzo Ink Exclusive License for DB-1418/AVZO-1418
On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced...
Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418
US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an...
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the...
GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets
GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics,...
GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324
UK-based GSK plc (NYSE: GSK) has entered into an exclusive option agreement with Duality Biologics,...
Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline
Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...
Duality Biotherapeutics’ BDCA2 ADC DB-2304 Phase I Trial Registered on ClinicalTrials.gov
Duality Biologics, Inc., a biopharmaceutical company specializing in the development of innovative therapies, has registered...
Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors
Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...
Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials
HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...
Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer
The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...
BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers
German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd...
BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305
Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing...
Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies
China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...
BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs
Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...